Less Ads, More Data, More Tools Register for FREE

Pin to quick picksWameja Di Regulatory News (WJA)

  • There is currently no data for WJA

Appendix 3B

15 Jun 2018 07:00

RNS Number : 5188R
eServGlobal Limited
15 June 2018
Β 

Rule 2.7, 3.10.3, 3.10.4, 3.10.5

Appendix 3B

Β 

New issue announcement,

application for quotation of additional securities

and agreement

Β 

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Β 

Β 

Name of entity

eServGlobal Limited

Β 

ABN

59 052 947 743

Β 

We (the entity) give ASX the following information.

Β 

Β 

Part 1 ‑ All issues

You must complete the relevant sections (attach sheets if there is not enough space).

Β 

1

+Class of +securities issued or to be issued

Β 

Performance Options

Β 

Β 

2

Number of +securities issued or to be issued (if known) or maximum number which may be issued

Β 

15,000,000

Β 

3

Principal terms of the +securities (e.g. if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion)

Unlisted options to acquire one ordinary fully paid share in the capital of eServGlobal Limited for each Option on the following terms:

Β 

Exercise Price: Β£0.09

Β 

Testing Date: the earlier of 30 September 2020 or the date of:

Β· a sale of substantially all of the business, or substantially all of the assets, of the Company; or

Β· A change of control of the Company.

Β 

Exercise Period: Subject to satisfaction of the Performance Conditions and the Tenure Conditions, from the Testing Date to the Expiry Date:

Β 

Expiry Date: 31 October 2022.

Β 

The Exercise Price or the number of ordinary fully paid shares in respect to which the option may be exercised may be reorganised in accordance with ASX Listing Rule 7.22.

Β 

The complete terms and conditions, including the Performance Conditions and Tenure Conditions are as described in the Explanatory Memorandum to the Company's Notice of Annual General Meeting dated 16 April 2018.

Β 

Β 

4

Do the +securities rank equally in all respects from the +issue date with an existing +class of quoted +securities?

Β 

If the additional +securities do not rank equally, please state:

Β· the date from which they do

Β· the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment

Β· the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

No

Β 

Β 

5

Issue price or consideration

Β 

Nil

Β 

Β 

6

Purpose of the issue

(If issued as consideration for the acquisition of assets, clearly identify those assets)

Β 

Β 

Β 

Β 

Β 

Β 

Issued as part of the remuneration of the Executive Chairman and Chief Financial Officer.

Β 

Β 

6a

Is the entity an +eligible entity that has obtained security holder approval under rule 7.1A?

Β 

If Yes, complete sections 6b - 6h in relation to the +securities the subject of this Appendix 3B, and comply with section 6i

Yes

Β 

Β 

6b

The date the security holder resolution under rule 7.1A was passed

17 May 2018

Β 

Β 

6c

Number of +securities issued without security holder approval under rule 7.1

Nil

Β 

Β 

6d

Number of +securities issued with security holder approval under rule 7.1A

Nil

Β 

Β 

6e

Number of +securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)

Β 

12,000,000 Performance Options pursuant to approval obtained under Listing Rule 10.14 on 17 May 2018

Β 

Β 

6f

Number of +securities issued under an exception in rule 7.2

Nil

Β 

Β 

6g

If +securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the +issue date and both values. Include the source of the VWAP calculation.

Not Applicable

Β 

Β 

6h

If +securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements

-

Β 

Β 

6i

Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A - complete Annexure 1 and release to ASX Market Announcements

226,712,665

Β 

7

+Issue dates

Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.

Cross reference: item 33 of Appendix 3B.

15 June 2018

Number

+Class

8

Number and +class of all +securities quoted on ASX (including the +securities in section 2 if applicable)

Β 

Β 

Β 

906,850,662

Β 

Ordinary Fully Paid Shares

Β 

Β 

Β 

Number

+Class

9

Number and +class of all +securities not quoted on ASX (including the +securities in section 2 if applicable)

Β 

Β 

Β 

11,000,000

Β 

Β 

7,225,000

Β 

Β 

15,000,000

Executive Options exercisable for $0.21

Β 

Employee Options exercisable for $0.21

Β 

Performance Options exercisable for Β£0.09

10

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

N/A

Β 

Part 2 ‑ Pro rata issue

Β 

11

Is security holder approval required?

Β 

-

12

Is the issue renounceable or non-renounceable?

-

13

Ratio in which the +securities will be offered

-

14

+Class of +securities to which the offer relates

-

15

+Record date to determine entitlements

-

Β 

16

Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?

-

17

Policy for deciding entitlements in relation to fractions

Β 

-

18

Names of countries in which the entity has security holders who will not be sent new offer documents

Note: Security holders must be told how their entitlements are to be dealt with.

Cross reference: rule 7.7.

-

19

Closing date for receipt of acceptances or renunciations

-

20

Names of any underwriters

Β 

Β 

-

21

Amount of any underwriting fee or commission

-

22

Names of any brokers to the issue

Β 

Β 

-

23

Fee or commission payable to the broker to the issue

-

24

Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders

-

25

If the issue is contingent on security holders' approval, the date of the meeting

-

26

Date entitlement and acceptance form and offer documents will be sent to persons entitled

-

27

If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders

-

28

Date rights trading will begin (if applicable)

-

29

Date rights trading will end (if applicable)

Β 

Β 

-

30

How do security holders sell their entitlements in full through a broker?

-

31

How do security holders sell part of their entitlements through a broker and accept for the balance?

-

Β 

32

How do security holders dispose of their entitlements (except by sale through a broker)?

-

33

+Issue date

Β 

Β 

-

Β 

Β 

Part 3 ‑ Quotation of securities

You need only complete this section if you are applying for quotation of securities

Β 

34

Type of +securities

(tick one)

Β 

(a)

+Securities described in Part 1

Β 

(b)

All other +securities

Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

Β 

Entities that have ticked box 34(a)

Β Additional securities forming a new class of securities

Β 

Β 

Tick to indicate you are providing the information or documents

Β 

35

If the +securities are +equity securities, the names of the 20 largest holders of the additional +securities, and the number and percentage of additional +securities held by those holders

36

If the +securities are +equity securities, a distribution schedule of the additional +securities setting out the number of holders in the categories

1 - 1,000

1,001 - 5,000

5,001 - 10,000

10,001 - 100,000

100,001 and over

37

A copy of any trust deed for the additional +securities

Β 

Β 

Β 

Entities that have ticked box 34(b)

Β 

38

Number of +securities for which +quotation is sought

Β 

Β 

Β 

39

+Class of +securities for which quotation is sought

Β 

Β 

Β 

40

Do the +securities rank equally in all respects from the +issue date with an existing +class of quoted +securities?

Β 

If the additional +securities do not rank equally, please state:

Β· the date from which they do

Β· the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment

Β· the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

Β 

Β 

41

Reason for request for quotation now

Example: In the case of restricted securities, end of restriction period

Β 

(if issued upon conversion of another +security, clearly identify that other +security)

Β 

Β 

Β 

Number

+Class

42

Number and +class of all +securities quoted on ASX (including the +securities in clause 38)

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Quotation agreement

Β 

1 +Quotation of our additional +securities is in ASX's absolute discretion. ASX may quote the +securities on any conditions it decides.

Β 

2 We warrant the following to ASX.

Β 

Β· The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.

Β 

Β· There is no reason why those +securities should not be granted +quotation.

Β 

Β· An offer of the +securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

Β 

Β· Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any +securities to be quoted and that no-one has any right to return any +securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the +securities be quoted.

Β 

Β· If we are a trust, we warrant that no person has the right to return the +securities to be quoted under section 1019B of the Corporations Act at the time that we request that the +securities be quoted.

Β 

3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.

Β 

4 We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before +quotation of the +securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Β 

Β 

Sign here: Date: 15 June 2018

(Company Secretary)

Β 

Print name: Tom Rowe

Β 

== == == == ==

Β 

Appendix 3B - Annexure 1

Β 

Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

Β 

Part 1

Β 

Rule 7.1 - Issues exceeding 15% of capital

Step 1: Calculate "A", the base figure from which the placement capacity is calculated

Insert number of fully paid +ordinary securities on issue 12 months before the +issue date or date of agreement to issue

640,183,996

Β 

Add the following:

β€’ Number of fully paid +ordinary securities issued in that 12 month period under an exception in rule 7.2

β€’ Number of fully paid +ordinary securities issued in that 12 month period with shareholder approval

β€’ Number of partly paid +ordinary securities that became fully paid in that 12 month period

Note:

β€’ Include only ordinary securities here - other classes of equity securities cannot be added

β€’ Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed

β€’ It may be useful to set out issues of securities on different dates as separate line items

Β 

213,177,639 (2017 pro rata entitlements offer)

53,272,003 Institutional Placement

217,024 Clawback Placement

Subtract the number of fully paid +ordinary securities cancelled during that 12 month period

0

"A"

906,850,662

Β 

Step 2: Calculate 15% of "A"

"B"

0.15

[Note: this value cannot be changed]

Multiply "A" by 0.15

136,027,599

Step 3: Calculate "C", the amount of placement capacity under rule 7.1 that has already been used

Insert number of +equity securities issued or agreed to be issued in that 12 month period not counting those issued:

β€’ Under an exception in rule 7.2

β€’ Under rule 7.1A

β€’ With security holder approval under rule 7.1 or rule 7.4

Note:

β€’ This applies to equity securities, unless specifically excluded - not just ordinary securities

β€’ Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed

β€’ It may be useful to set out issues of securities on different dates as separate line items

Nil

"C"

Nil

Step 4: Subtract "C" from ["A" x "B"] to calculate remaining placement capacity under rule 7.1

"A" x 0.15

Note: number must be same as shown in Step 2

136,027,599

Subtract "C"

Note: number must be same as shown in Step 3

Nil

Total ["A" x 0.15] - "C"

136,027,599

[Note: this is the remaining placement capacity under rule 7.1]

Β 

Β 

Β 

Β 

Β 

Part 2

Β 

Rule 7.1A - Additional placement capacity for eligible entities

Step 1: Calculate "A", the base figure from which the placement capacity is calculated

"A"

Note: number must be same as shown in Step 1 of Part 1

906,850,662

Step 2: Calculate 10% of "A"

"D"

0.10

Note: this value cannot be changed

Multiply "A" by 0.10

90,685,066

Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used

Insert number of +equity securities issued or agreed to be issued in that 12 month period under rule 7.1A

Notes:

β€’ This applies to equity securities - not just ordinary securities

β€’ Include here - if applicable - the securities the subject of the Appendix 3B to which this form is annexed

β€’ Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained

β€’ It may be useful to set out issues of securities on different dates as separate line items

Nil

"E"

Nil

Β 

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A

"A" x 0.10

Note: number must be same as shown in Step 2

90,685,066

Subtract "E"

Note: number must be same as shown in Step 3

Nil

Total ["A" x 0.10] - "E"

90,685,066

Note: this is the remaining placement capacity under rule 7.1A

Β 

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
Β 
END
Β 
Β 
MSCFAMJTMBBBMLP
Date   Source Headline
22nd Sep 20178:30 amRNSHolding(s) in Company
13th Jul 201711:32 amRNSChange in substantial holding - Amendment
13th Jul 201711:02 amRNSChange in substantial holding
10th Jul 20177:00 amRNSChange in substantial holding
29th Jun 20177:00 amRNSH1 Report & Commentary, Debt Extension & Outlook
8th Jun 20171:43 pmRNSChange in substantial holding
11th May 20177:00 amRNSGuarantees Credit Facility to HomeSend
12th Apr 20177:00 amRNSAppendix 3B - Executive Options
15th Mar 20177:00 amRNSInvestor event recorded presentation
13th Mar 20177:16 amRNSResult of AGM
13th Mar 20177:00 amRNSAGM Statement
7th Mar 20177:00 amRNSInvestor Event
17th Feb 20177:00 amRNSAnnual Financial Report
15th Feb 20177:00 amRNSChange to Financial Year End
10th Feb 20177:00 amRNSNotice of AGM
31st Jan 20177:00 amRNSFull Year Statutory Accounts
21st Dec 20167:18 amRNSDirector Appointment
20th Dec 20167:00 amRNSResults Commentary FY2016
20th Dec 20167:00 amRNSPreliminary Final Report
7th Nov 20167:00 amRNSTrading Update
28th Sep 20167:00 amRNSHomeSend announce partnership with Ericsson
21st Sep 20163:00 pmRNSHomeSend announces remittance service in Ethiopia
12th Sep 20163:40 pmRNSHomeSend secures partnership with KEB Hana Bank
12th Aug 20167:00 amRNSAppendix 3B- Shortfall Shares
9th Aug 20167:00 amRNSAppendix 3B- Executive and Employee Options
8th Aug 20168:00 amRNSDirector Dealing
8th Aug 20167:00 amRNSAppendix 3B
5th Aug 20167:34 amRNSResult of Open Offer & Total Voting Rights
4th Aug 20167:04 amRNSNotice of under subscriptions for Open Offer
26th Jul 20167:00 amRNSNotice under s708A(5)(e) of the Corporations Act
25th Jul 20167:00 amRNSAppendix 3B
22nd Jul 20167:00 amRNSResult of EGM and Total Voting Rights
30th Jun 20167:00 amRNSResults Commentary
30th Jun 20167:00 amRNSHalf-year Report
22nd Jun 20167:00 amRNSNotice of EGM and Posting of Open Offer Circular
16th Jun 20167:00 amRNSNotice under Section 708A(5)(e) Corporations Act
16th Jun 20167:00 amRNSAppendix 3B- Firm Placing Shares
15th Jun 20167:00 amRNSShareholder Letters- Open Offer
14th Jun 20167:00 amRNSNotice under Section708AA(2)(f) Corporations Act
14th Jun 20167:00 amRNSAppendix 3B- Open Offer
14th Jun 20167:00 amRNSClarification of terms of Open Offer
7th Jun 20162:00 pmRNSProposed Placings, Open Offer and Debt Restructure
26th May 20168:35 amRNSeServGlobal and Zain win GTB Innovation Award
18th May 20167:00 amRNSTrading Update
4th May 20162:21 pmRNSeServGlobal wins new contract in West Africa
22nd Apr 20167:00 amRNSeServGlobal announces new contract win
20th Apr 201611:31 amRNSHolding(s) in Company
11th Apr 20168:08 amRNSChange of Director's Interest Notice
11th Apr 20168:08 amRNSAppendix 3B
11th Apr 20167:12 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.